Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2025-07-01 Investor Presentation
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Remplir US Rollout & 1st Surgery Investor Update 20 pages 1.6MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation focused on the US commercialization update of Orthocell's Remplir product. It includes market opportunity, clinical results, manufacturing, logistics, and sales strategy. There are no financial statements, regulatory filings, or voting results. The content is typical of an investor or commercial update presentation rather than a formal financial report or regulatory filing. The length (15,000 characters) and detailed content confirm it is a full presentation, not a brief announcement or certification. Therefore, the document best fits the category of an Investor Presentation (IP).
2025-07-01 English
Record Revenue of $2.73m in June 25 Quarter up 22.8% QoQ 4 pages 351.3KB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of Orthocell's record revenue for the June quarter ended 30 June 2025, including specific financial figures, growth rates, and market expansion details. It contains substantive financial data such as quarterly revenue amounts, growth percentages, and cash position. The document also discusses operational progress, market penetration, and future sales expectations. It is not merely an announcement of a report or a brief summary but provides comprehensive financial performance information for a quarterly period. There is no indication that this is a full annual report or audit report, nor is it a transcript or management change announcement. The presence of detailed quarterly financial results and analysis aligns with the definition of an Interim / Quarterly Report (IR). The document length (over 10,000 characters) and content confirm it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2025-06-30 English
First Surgical Use of Remplir in US$1.6 Billion US Market 3 pages 231.8KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the first surgical use of Orthocell's nerve repair product Remplir in the US following FDA clearance. It discusses commercial rollout plans, market size, distributor network, and future sales expectations. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The content is focused on a product launch and commercial update rather than financial results or governance matters. It is not a report publication announcement since it does not mention the release or availability of a report. The document fits best as a Capital/Financing Update (CAP) because it provides an update on the commercial rollout and sales growth prospects related to the company's product and market expansion, which is related to capitalizing on the product in the market.
2025-06-26 English
Investor Webinar 2 pages 218.0KB
Investor Presentation Classification · 90% confidence The document is a press release announcing a webinar event by Orthocell Limited to provide an overview of its first US surgical use of Remplir™ and an update on the US rollout. It includes details about the webinar date, time, registration, and contact information. There is no financial data, no detailed report content, no regulatory filing, no voting results, no management changes, and no audit or earnings information. The document is short (4580 characters) and serves as an announcement of an upcoming investor presentation event rather than the presentation itself or a report. Therefore, it fits best under the category of Investor Presentation (IP) as it is a briefing for investors focusing on company updates and strategy, even though the actual presentation will occur later. Confidence is high given the clear nature of the document as an investor briefing announcement.
2025-06-26 English
Compelling Data Highlights Remplir Competitive Advantage 4 pages 288.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing interim study results on the superiority of a medical product (Remplir) over the standard nerve repair technique. It contains detailed scientific and clinical data from a study, including methodology, results, and implications for market rollout. The document is not a financial report, regulatory filing, or management discussion of financial results. It is not an earnings release, annual report, or interim financial report. It is a corporate announcement focused on clinical study results and product development progress, which does not fit into categories related to financial or governance filings. The document is a detailed announcement of scientific study results supporting product marketing and sales efforts, which is best classified as a Regulatory Filing (RNS) because it does not fit any other specific category and is a general corporate announcement with substantive content.
2025-06-18 English
Application for quotation of securities - OCC 9 pages 23.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement from Orthocell Limited regarding the application for quotation of securities on the ASX. It details the securities issued as a result of options being exercised or convertible securities being converted, including numbers, issue dates, and other related information. The document is a formal regulatory announcement related to securities quotation and issuance, not a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, which cover new share issues and related capital changes.
2025-06-09 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.